KTX-1001 + carfilzomib + dexamethasone

KTX-1001 + carfilzomib + dexamethasone is an investigational combination therapy currently in Phase 1 clinical trials for relapsed and refractory multiple myeloma, with a focus on patients with the t(4;14) chromosomal translocation. KTX-1001 is a first-in-class, oral, selective, small molecule inhibitor of the lysine methyltransferase NSD2 (also known as MMSET), designed to reduce H3K36me2 levels and restore balanced gene expression. Carfilzomib is a second-generation, selective proteasome inhibitor used in multiple myeloma regimens, and dexamethasone is a synthetic glucocorticoid with anti-inflammatory and cytotoxic lympholytic activity. The combination aims to target high-risk multiple myeloma biology through simultaneous epigenetic modulation (KTX-1001), proteasome inhibition (carfilzomib), and corticosteroid activity (dexamethasone). KTX-1001 is developed by K36 Therapeutics; carfilzomib is developed by Onyx Pharmaceuticals/Amgen; dexamethasone is generic and widely manufactured. The trial is evaluating safety, pharmacokinetics, and efficacy outcomes in the target population[1][2][3][4].

Other names

carfilzomibdexamethasone